WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the...Read more
TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development Multiple TNG462 combination studies planned in 1H 2025 Clinical...Read more
Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-end Additional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov....Read more
NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban...Read more
This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the...Read more
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Medpace | 30.03 9.15 | $358.27 |
| UnitedHealth | 29.66 5.23 | $596.69 |
| Humana | 27.91 10.71 | $288.51 |
| Charles River Laboratories | 25.52 13.53 | $214.20 |
| McKesson | 24.03 4.57 | $549.31 |
| ZIVO Bioscience | 18.40 1,672.73 | $19.50 |
| Chemed | 16.82 3.15 | $549.99 |
| Masimo | 16.07 10.60 | $167.63 |
| United Therapeutics | 14.72 3.85 | $397.49 |
| U.S. Physical Therapy | 14.57 17.65 | $97.10 |
| Glaukos | 12.78 10.00 | $140.64 |
| Inspire Medical Systems | 12.63 6.35 | $211.63 |
| Tempus AI | 12.47 28.02 | $56.97 |
| Mettler-Toledo | 12.40 0.89 | $1,398.19 |
| Elevance Health | 11.16 2.67 | $428.93 |
| Belite Bio | 10.98 15.66 | $81.08 |
| Finch Therapeutics | 10.20 566.67 | $12.00 |
| National HealthCare | 9.41 7.78 | $130.34 |
| Company | Volume | Last Trade |
|---|---|---|
| Pfizer | 56,429,480 | $27.36 |
| Cardio Diagnostics | 50,741,539 | $0.36 |
| LifeWallet | 39,193,614 | $0.12 |
| Vyome | 36,361,564 | $0.22 |
| CVS Health | 26,184,508 | $61.61 |
| Sonnet BioTherapeutics | 24,847,803 | $3.73 |
| Walgreens Boots Alliance | 21,158,442 | $9.23 |
| Bluejay Diagnostics | 19,907,928 | $0.09 |
| Teva Pharmaceutical | 17,559,156 | $17.43 |
| Bionomics | 17,050,060 | $0.28 |
| Exact Sciences | 16,560,836 | $54.72 |
| AstraZeneca | 15,014,215 | $63.85 |
| Tango Therapeutics | 14,843,017 | $3.24 |
| PacBio | 14,468,905 | $2.65 |
| Clover Health | 14,247,400 | $4.35 |
| GSK | 13,860,483 | $35.90 |
| Oscar Health | 12,128,938 | $15.55 |
| Shineco | 12,127,008 | $0.15 |
| Sangamo Therapeutics | 11,934,285 | $2.47 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
